Monte Rosa Therapeutics Inc (NASDAQ:GLUE)’s traded shares stood at 1.15 million during the last session, with the company’s beta value hitting 1.38. At the close of trading, the stock’s price was $9.24, to imply a decrease of -6.29% or -$0.62 in intraday trading. The GLUE share’s 52-week high remains $12.40, putting it -34.2% down since that peak but still an impressive 68.07% since price per share fell to its 52-week low of $2.95. The company has a valuation of $567.68M, with an average of 1.19 million shares in intraday trading volume over the past 10 days and average of 2.32 million shares over the past 3 months.
Analysts have given a consensus recommendation of Buy for Monte Rosa Therapeutics Inc (GLUE), translating to a mean rating of 1.00. Of 5 analyst(s) looking at the stock, 0 analyst(s) give GLUE a Sell rating. 0 of those analysts rate the stock as Overweight while 1 advise Hold as 4 recommend it as a Buy. 0 analyst(s) have given it an Underweight rating. Estimates put the company’s current-quarter earnings per share at 0.2.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Monte Rosa Therapeutics Inc (NASDAQ:GLUE) trade information
After registering a -6.29% downside in the last session, Monte Rosa Therapeutics Inc (GLUE) has traded red over the past five days. The 5-day price performance for the stock is 7.44%, and 4.52% over 30 days. With these gigs, the year-to-date price performance is 63.54%. Short interest in Monte Rosa Therapeutics Inc (NASDAQ:GLUE) saw shorts transact 11.15 million shares and set a 2.23 days time to cover.
Monte Rosa Therapeutics Inc (GLUE) estimates and forecasts
Looking at statistics comparing Monte Rosa Therapeutics Inc share performance against respective industry, we note that the company has outperformed competitors. Monte Rosa Therapeutics Inc (GLUE) shares are 125.92% up over the last 6 months, with its year-to-date growth rate higher than industry average at 43.35% against 17.30%.
Revenue forecast for the current quarter as set by 7 analysts is 51.19M. Meanwhile, for the current quarter, a total of 4 analyst(s) estimate revenue growth to 6.1M.
GLUE Dividends
Monte Rosa Therapeutics Inc has its next earnings report out in January. However, it is important to take into account that this dividend yield ratio is just an indicator to only serve the purpose of guidance. Investors interested to invest in the stock should ponder company’s other fundamental and operations related aspects too.
Monte Rosa Therapeutics Inc (NASDAQ:GLUE)’s Major holders
Monte Rosa Therapeutics Inc insiders hold 0.70% of total outstanding shares, with institutional holders owning 90.62% of the shares at 91.27% float percentage. In total, 90.62% institutions holds shares in the company, led by NEA MANAGEMENT COMPANY, LLC. As of 2024-06-30, the company held over 7.69 million shares (or 12.7872% of shares), all amounting to roughly $28.77 million.
The next major institution holding the largest number of shares is PRICE T ROWE ASSOCIATES INC /MD/ with 5.98 million shares, or about 9.9368% of shares outstanding. As of the market price on 2024-06-30, these shares were worth $22.36 million.
